Novel PET Imaging of Glucose Transport

葡萄糖转运的新型 PET 成像

• 批准号: 8322155
• 负责人: FARAMARZ ISMAIL-BEIGI
• 金额: $ 33.47万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8322155
• 关键词: 2-Fluoro-2-deoxyglucose; 6-deoxyglucose; Animal Model; Animals; Applications Grants; Biochemical; Biodistribution; Biological Assay; Blood; Blood Vessels; Brain; Carbon; Cell Culture Techniques; Clinical; Cyclotrons; Data; Data Collection; Deoxyglucose; Development; Diabetes Mellitus; Discrimination; Disease; Disease Progression; Dose; Energy-Generating Resources; Epidemic; Excretory function; Experimental Models; Eye; Future; GLUT4 gene; Glucose; Glucose Transporter; Goals; Gold; Half-Life; Heart; Hexokinase 2; Human; Hydroxyl Radical; Hyperglycemia; Image; In Vitro; Individual; Injection of therapeutic agent; Insulin; Insulin Resistance; Kidney; Kinetics; Label; Lead; Maintenance; Malignant Neoplasms; Mammalian Cell; Measurement; Measures; Metabolism; Methodology; Methods; Modeling; Monitor; Myocardium; Nerve; Non-Insulin-Dependent Diabetes Mellitus; Nuclear Magnetic Resonance; Obesity; Organ; Patients; Pharmaceutical Preparations; Phosphorylation; Physiological; Positron-Emission Tomography; Protocols documentation; Radiation; Radioactive; Radioactivity; Radiolabeled; Radiopharmaceuticals; Rattus; Research; Running; SLC2A1 gene; Safety; Series; Site; Skeletal Muscle; Spectrum Analysis; Streptozocin; Testing; Time; Tissue Sample; Tissues; Tracer; United States; Urine; Validation; abstracting; base; bone; diabetic; dosage; glucose analog; glucose metabolism; glucose transport; hexokinase; in vivo; insight; interstitial; mathematical model; novel; pre-clinical; radiotracer; response; sugar; uptake; urinary

Abstract Diabetes mellitus is an epidemic in the United States and the world. Type 2 diabetes, the most prevalent form of diabetes, is commonly associated with insulin resistance that often precedes the onset of overt hyperglycemia. Here we propose to further develop and employ a PET-scanning-based methodology to measure glucose transport in skeletal muscle, heart and other tissues under normal and insulin-resistant states. The method has two components: a radiopharmaceutical and a mathematical model. Specifically, we have developed a new radiopharmaceutical 18F-labeled 6-fluoro-6-deoxy-D-glucose ([18F]6FDG) so that the bio- and kinetic distribution of the compound can be quantitatively measured with positron emission tomography (PET). [18F]6FDG, unlike 2-fluoro-2-deoxy-D-glucose ([18F]2FDG) that is commonly used in PET studies, lacks a hydroxyl on carbon 6, and hence is transported but not phosphorylated. The new model relates the PET-measured time-course of radioactive glucose analogs, [18F]6FDG and [18F]2FDG, to the fluxes, transport capacities, phosphorylation and concentrations of glucose. Our overall objective is to validate and apply methodologies for the in vivo quantification of glucose transport, phosphorylation and interstitial and intracellular concentrations in skeletal muscle, heart and brain in normal and abnormal conditions. We use biochemical analyses, in vitro transporter assays, in vivo animal models, PET scanning and mathematical models. We will also perform preclinical and clinical PET studies. Importantly, the PET scan data will enable us to calculate the effect of insulin and other agents on the rate of glucose transport in the above tissues in normal and disease states. The goal is to establish a method that can be used in vivo in humans to determine influx and efflux rates of glucose, intracellular and interstitial concentrations of glucose, the phosphorylation rate of glucose, and most importantly, the maximal glucose transport capacity (Vmax) from the time-series of PET images following sequential injections of [18F]6FDG and [18F]2FDG. Determination of insulin-stimulated glucose transport will provide insight into mechanisms underlying abnormal glucose metabolism in diabetes and will enable monitoring the progression of the disease and its response to specific treatments. Hence, progress on this grant proposal will significantly contribute to our ability to evaluate and optimally manage patients at the individual level.

摘要

项目成果

Analysis of metabolism of 6FDG: a PET glucose transport tracer.

• DOI: 10.1016/j.nucmedbio.2010.12.007
• 发表时间: 2011-07
• 期刊: Nuclear medicine and biology
• 影响因子: 3.1
• 作者: Muzic RF Jr;Chandramouli V;Huang HM;Wu C;Wang Y;Ismail-Beigi F
• 通讯作者: Ismail-Beigi F

Human radiation dosimetry of 6-[18F]FDG predicted from preclinical studies.

根据临床前研究预测的 6-[18F]FDG 人体辐射剂量测定。

• DOI: 10.1118/1.4866217
• 发表时间: 2014
• 期刊: Medical physics
• 影响因子: 3.8
• 作者: MuzicJr,RaymondF;Chandramouli,Visvanathan;Huang,Hsuan-Ming;Wu,Chunying;Hatami,Ahmad;Ismail-Beigi,Faramarz
• 通讯作者: Ismail-Beigi,Faramarz